Literature DB >> 9727987

Which contacts of patients with meningococcal disease carry the pathogenic strain of Neisseria meningitidis? A population based study.

B E Kristiansen1, Y Tveten, A Jenkins.   

Abstract

OBJECTIVES: To determine the prevalence of the pathogenic strain of Neisseria meningitidis in contacts of patients with meningococcal disease, and to determine which contact groups are likely to be carriers and warrant chemoprophylaxis.
DESIGN: Population based study.
SETTING: Norwegian county of Telemark.
SUBJECTS: 1535 primary contacts of 48 patients with meningococcal disease, and 78 secondary contacts.
INTERVENTIONS: Carriers of the pathogenic strain were treated with rifampicin. All household members and kissing contacts under 15 years of age were treated with oral penicillin. Contacts were taught to recognise the symptoms of meningococcal disease.
RESULTS: In 27 of 48 cases investigated, contacts carrying the pathogenic strain of N meningitidis were found. A total of 42 such contacts were identified. Contacts were stratified into three classes according to the assumed closeness of contact with patients. In class 1 (household members and kissing contacts) the prevalence of the pathogenic strain was 12.4% (95% confidence interval 5.5% to 19.3%). In classes 2 and 3 the prevalence was 1.9% (0.9% to 3.4%) and 1.6% (0.14% to 3.1%).
CONCLUSIONS: There is a high rate of carriage of the pathogenic strain of N meningitidis in patients' household members and kissing contacts, and this supports the practice of giving chemoprophylaxis to these contacts. The prevalence of carriage among other contacts is 2-3 times that found in the general population (0.7%); the benefits of chemoprophylaxis to these contacts may be marginal.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9727987      PMCID: PMC28653          DOI: 10.1136/bmj.317.7159.621

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  18 in total

1.  Antibiotic prophylaxis for bacterial meningitis: overuse and uncertain efficacy.

Authors:  N Pearson; D J Gunnell; C Dunn; T Beswick; A Hill; B Ley
Journal:  J Public Health Med       Date:  1995-12

2.  Optimising the investigation of meningococcal disease.

Authors:  K Cartwright; S Kroll
Journal:  BMJ       Date:  1997-09-27

3.  Secondary cases of meningococcal infection among close family and household contacts in England and Wales, 1984-7.

Authors:  R P Cooke; T Riordan; D M Jones; M J Painter
Journal:  BMJ       Date:  1989-03-04

4.  Spread of meningococcal infection within households.

Authors:  R S Munford; A de E Taunay; J S de Morais; D W Fraser; R A Feldman
Journal:  Lancet       Date:  1974-06-22       Impact factor: 79.321

5.  Meningococcal disease. Secondary attack rate and chemoprophylaxis in the United States, 1974.

Authors: 
Journal:  JAMA       Date:  1976-01-19       Impact factor: 56.272

6.  Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population.

Authors:  D A Caugant; E A Høiby; P Magnus; O Scheel; T Hoel; G Bjune; E Wedege; J Eng; L O Frøholm
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

7.  Meningococcal carriage in close contacts of cases.

Authors:  K A Cartwright; J M Stuart; P M Robinson
Journal:  Epidemiol Infect       Date:  1991-02       Impact factor: 2.451

8.  Control of meningococcal disease: guidance for consultants in communicable disease control. PHLS Meningococcal Infections Working Group and Public Health Medicine Environmental Group.

Authors: 
Journal:  Commun Dis Rep CDR Rev       Date:  1995-12-08

9.  Meningococcal phenotypic and genotypic characteristics and human antibody levels.

Authors:  B E Kristiansen; K W Lind; K Mevold; B Sørensen; L O Frøholm; K Bryn; T Tjade; K Bøvre
Journal:  J Clin Microbiol       Date:  1988-10       Impact factor: 5.948

10.  Meningococcal disease in Belgium. Secondary attack rate among household, day-care nursery and pre-elementary school contacts.

Authors:  P De Wals; L Hertoghe; I Borlée-Grimée; S De Maeyer-Cleempoel; G Reginster-Haneuse; A Dachy; A Bouckaert; M F Lechat
Journal:  J Infect       Date:  1981-03       Impact factor: 6.072

View more
  10 in total

1.  Carriage of meningococci in contacts of patients with meningococcal disease. "Kissing contacts" need to be defined.

Authors:  A Hayward
Journal:  BMJ       Date:  1999-03-06

2.  Development of immunity to serogroup B meningococci during carriage of Neisseria meningitidis in a cohort of university students.

Authors:  J Zoe Jordens; Jeannette N Williams; Graeme R Jones; Myron Christodoulides; John E Heckels
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

3.  Total antioxidant capacity of plasma in asymptomatic carrier state of Neisseria meningitidis.

Authors:  J Uberos; A Molina-Carballo; G Galdo-Muñoz; A Muñoz-Hoyos
Journal:  Epidemiol Infect       Date:  2006-11-17       Impact factor: 2.451

4.  Risk and prevention of meningococcal disease among education workers: A review.

Authors:  Philippe De Wals; Pierre Deshaies; Gaston De Serres; Bernard Duval; Lise Goulet; Bernard Pouliot; Sylvie Ricard; Maurice Poulin
Journal:  Can J Infect Dis       Date:  2004-03

5.  Carriers of Neisseria meningitidis in household contacts of meningococcal disease cases in Catalonia (Spain).

Authors:  N Cardeñosa; A Domínguez; A Orcau; H Pañella; P Godoy; S Minguell; N Camps; J A Vázquez
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

6.  Invasive meningococcal disease in elderly people, New South Wales, Australia, 1993 to 2012.

Authors:  Praveena Gunaratnam; Peter Massey; David Durrheim; Siranda Torvaldsen
Journal:  Western Pac Surveill Response J       Date:  2013-12-09

7.  Meningococcal disease serogroup C.

Authors:  Félix O Dickinson; Antonio E Pérez; Iván E Cuevas
Journal:  Risk Manag Healthc Policy       Date:  2012-03-08

8.  Variations in chemoprophylaxis for meningococcal disease: a retrospective case note review, analysis of routine prescribing data and questionnaire of general practitioners.

Authors:  P J Marks; K R Neal
Journal:  BMC Public Health       Date:  2001-12-11       Impact factor: 3.295

9.  Protocol for a controlled human infection with genetically modified Neisseria lactamica expressing the meningococcal vaccine antigen NadA: a potent new technique for experimental medicine.

Authors:  Diane Gbesemete; Jay Robert Laver; Hans de Graaf; Muktar Ibrahim; Andrew Vaughan; Saul Faust; Andrew Gorringe; Robert Charles Read
Journal:  BMJ Open       Date:  2019-05-01       Impact factor: 2.692

10.  Mass vaccination campaign following community outbreak of meningococcal disease.

Authors:  Gérard Krause; Carina Blackmore; Steven Wiersma; Cheryll Lesneski; Laurey Gauch; Richard S Hopkins
Journal:  Emerg Infect Dis       Date:  2002-12       Impact factor: 6.883

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.